Dash Pramod K, Kobori Nobuhide, Moore Anthony N
Department of Neurobiology and Anatomy, and The Vivian L. Smith Center for Neurologic Research, The University of Texas Medical School, Houston, Texas 77225, USA.
Neurochem Res. 2004 Jun;29(6):1275-86. doi: 10.1023/b:nere.0000023614.30084.eb.
It has been estimated that 50% of human transcriptome, the collection of mRNA in a cell, is expressed in the brain, making it one of the most complex organs to understand in terms of genomic responses to injury. The availability of genome sequences for several organisms coupled with the increasing affordability of microarray technologies makes it feasible to monitor the mRNA levels of thousands of genes simultaneously. In this paper, we provide an overview of findings using both cDNA- and oligonucleotide-based microarray analyses after experimental traumatic brain injury (TBI). Specifically, the utility of this methodology as a means of cataloging the biochemical sequelae of brain trauma and elucidating novel genes or pathways for further study is discussed. Furthermore, we offer future directions for the continued evaluation of microarray results and discuss the usefulness of microarray techniques as a testing format for determining the efficacy of mechanism-based therapies.
据估计,人类转录组(细胞中mRNA的集合)的50%在大脑中表达,这使得大脑成为就基因组对损伤的反应而言最难理解的器官之一。几种生物的基因组序列的可得性,再加上微阵列技术成本的不断降低,使得同时监测数千个基因的mRNA水平成为可能。在本文中,我们概述了实验性创伤性脑损伤(TBI)后基于cDNA和寡核苷酸的微阵列分析的研究结果。具体而言,讨论了这种方法作为一种编目脑损伤生化后遗症以及阐明新基因或新通路以供进一步研究的手段的实用性。此外,我们为微阵列结果的持续评估提供了未来方向,并讨论了微阵列技术作为一种测试形式来确定基于机制的疗法疗效的有用性。